Pierre De BeaudrapAssane DioufKhady NiangK. Bousso Niang2026-03-222026-03-22201410.1007/s13149-014-0352-yhttps://doi.org/10.1007/s13149-014-0352-yhttps://andeanlibrary.org/handle/123456789/55655Citaciones: 2In 1998, the cohort ANRS 1215 was launched in Senegal with one of the first African antiretroviral treatment programs. Four hundred forty four HIV-infected adults started on ART were included between 1998 and 2004, and followed up to 2010. Mortality before 6 months was 15.6/100 person-year (PY) and associated to the initial disease severity. It decreased to 3.36/100 PY thereafter. The cumulative risks of virologic failure at 60 months and of drug resistance at 48 months were 25% and 16%, respectively.frCohortMedicineAntiretroviral therapyHuman immunodeficiency virus (HIV)Cohort studySidaDrug resistanceInternal medicinePediatricsViral diseasearticle